drugset / Trial / NCT06530849
A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus
Phase 1/2
Active not recruiting
20 enrolled
Gracell Biotechnologies (Shanghai) Co., Ltd.
AstraZeneca · collabSuzhou Gracell Biotechnologies Co., Ltd. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single-arm, open-label, multicenter, phase 1/2 clinical study to assess the safety and efficacy of GC012F Injection in subjects with refractory Systemic Lupus Erythematosus (SLE).
Timeline
- Start
- 2024-08-22
- Primary completion
- 2027-02-01
- Completion
- 2027-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GC012F Injection | Cell therapy | — | — |